Shanghai Fosun Pharmaceutical Group Co Ltd (2196.HK)
21 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|45||2016||Co-Chairman of the Board, Executive Director|
|48||2016||Co-Chairman of the Board|
|48||2016||President, Chief Executive Officer, Executive Director|
|46||2016||Chief Financial Officer, Senior Vice President, Chief Accounting Officer|
|42||Senior Vice President|
- BRIEF-Shanghai Fosun Pharmaceutical Group unit gets sole license on research of anticarcinogen in China
- REFILE-BRIEF-Shanghai Fosun Pharmaceutical's Unit Signs Agreement To Buy Stake In Foshan Hospital
- BRIEF-Shanghai Fosun Pharmaceutical Gets Regulatory Approval To Issue Up To 5.0 Bln Yuan Bonds
- BRIEF-Shanghai Fosun Pharmaceutical Group Co Says Two Units & Shanghai Yunji To Establishment A JV
- BRIEF-Shanghai Fosun Pharmaceutical's Unit To Invest In Amerigen Pharmaceuticals' Bonds